USFDA

The U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.

The U.S. Food and Drug Administration approved FluMist for self- or caregiver-administration. FluMist is approved for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age. FluMist is sprayed into the nose and has been used safely and effectively for many years. It was initially approved by the FDA in 2003 for use in individuals 5 through 49 years of age, and in 2007, the FDA approved the use of FluMist to include children 2 through 5 years of age.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India.

Eugia Pharma  receives a warning letter from FDA which summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals.

U.S. Food and Drug Administration (FDA) inspected a drug manufacturing facility of Eugia Pharma Specialities Limited (Unit III), at Patancheru (Mandal), Sangareddy, Hyderabad, Telangana, from January 22 to February 2, 2024. It is a wholly owned subsidiary of the Aurobindo Pharma.

Indoco Remedies receives final ANDA approval from the USFDA  for Lofexidine Tablets 0.18 mg with Competitive Generic Therapy designation, It is a generic equivalent of Lucemyra Tablets, 0.18 mg of USWM, LLC.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India.